Roche discontinues Fortovase
Executive Summary
Roche announced May 18 it will discontinue the sale and distribution of its HIV therapy Fortovase (saquinavir). Roche said clinical demand for the product has declined significantly due to the availability of a higher dose (500 mg) formulation of Invirase (saquinavir mesylate). Fortovase will be discontinued during the first quarter 2006. Fortovase was originally positioned as a successor product to Invirase...